The world’s largest and most influential biotechnology gathering, the 2014 BIO International
Conference, kicks off today in San Diego. BIO, the signature annual event of the Biotechnology Industry Organization (BIO) convenes biotech innovators and influencers from around the globe to explore solutions and meet service providers; gain new perspectives from thoughtful and thought-provoking leaders; find new partners and evaluate projects at all phases of development.
One of those innovators is David Johnson, CEO and Co-Founder of GigaGen, Inc. GigaGen has partnered with 5AM to develop ClonoByte, an Immune Repertoire Sequencing Management and Analysis Platform. The platform will give researchers a DNA-level view of the immune system and see what antibodies are being produced. This perspective can advance applications ranging from vaccine development to transplant tolerance to disease research and more.
GigaGen also developed GigaMune, a unique technology using microfluidics, bioinformatics, and next-generation sequencing to mine complete B cell repertoires for antibodies that are safer, more efficacious, and more biologically relevant.
If you’re at BIO, you can see ClonoByte in action. Dave Johnson will be demonstrating the platform at Booth 5449 in the BIO Innovation Zone.
The Innovation Zone is a collaboration between BIO, NIH, and the National Science Foundation which showcases early-stage Small Business Innovation Research (SBIR) funded biotechnology companies.
- Michele Downs
